09/29/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 9/29/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the LIAISON SARS-CoV-2 IgM. The LIAISON SARS-CoV-2 IgM is authorized for the detection of IgM antibodies to SARS-CoV-2 in human serum and plasma (sodium heparin, lithium heparin, and dipotassium EDTA). (PDF)
No hay comentarios:
Publicar un comentario